麻豆传媒

Nearly 70% of participants had at least a 30% reduction in PANSS total score by week 52

Trial data may expand use, with "opportunity to truly individualize treatment"

Lumateperone is already FDA approved for schizophrenia and bipolar disorder

Database study shows estimated 5-year survival of 78% even after one relapse episode

No approved agent has the same mechanism of action as seltorexant

First-year care trajectories looked different than those seeing psychiatrists

Nearly half of hesitant prescribers cited safety and tolerability as their top concern

Comorbidities may complicate treatment and diagnosis

Most patients on twice-a-year doses of paliperidone palmitate remained relapse-free over 3 years

Treatment should be prescribed with cardiovascular risks in mind, says researcher

Most adverse events dissipated after second or third treatment with intranasal esketamine

Symptoms had some PAs saying they intended to leave their clinical posts sooner rather than later

Youth on Jornay PM saw significantly higher weight trajectories

SHORELINE trial found reduced depression symptoms even in those exiting study early